On 3 July 2026, China NT Pharma Group Company Limited (NT Pharma) filed its Monthly Return for Equity Issuer covering the period ended 30 June 2026 with the Hong Kong Stock Exchange.

Authorised Capital • Ordinary shares authorised remained at 62.59 billion units with a par value of USD 0.0000008, representing USD 50,074 in nominal value. • Preference shares authorised stayed at 32.50 million units with the same par value, totalling USD 26. • Aggregate authorised share capital was unchanged at USD 50,100.

Issued Share Capital and Treasury Shares • Issued ordinary shares (excluding treasury shares) closed the month at 948.99 million, identical to the preceding month. • The company held no treasury shares, and there were no share issuances, cancellations, or repurchases during June.

Public Float Compliance NT Pharma confirmed that it continued to satisfy the Main Board’s minimum public float requirement of 25% of issued shares as at 30 June 2026.

Corporate Actions The filing reported no movements or outstanding instruments under share option schemes, warrants, convertibles, or other arrangements to issue shares. No Hong Kong Depositary Receipts were outstanding.

The monthly return was signed by Executive Director Ng Tit, affirming full compliance with all applicable listing and regulatory obligations.